Cromolyn
INTAL
What it isMast-cell stabilizer; prophylaxis for asthma and allergy, and symptom control in mastocytosis.
Why this oneMinimal systemic absorption gives it an unusually clean safety profile when local prophylaxis is enough.
What limits itIt does nothing for an acute attack and frequent dosing undermines adherence. Inhalation can provoke cough or bronchospasm.
FDA-approved for
- asthma/allergy (~1973)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Allergic ocular disorders (itching, tearing, redness, discharge) | — | 1–2 drops in each eye 4–6×/day at regular intervals | 1–2 drops each eye 4–6×/day | 1–2 drops each eye 6×/day |
Renal Undefined
Hepatic Undefined
Instructions
- Administer at regular intervals for effect
- Symptomatic response usually within a few days; up to 6 weeks may be required
- Corticosteroids may be used concomitantly if required
Cautions
- Immediate hypersensitivity reactions reported rarely (dyspnea, edema, rash)
Adverse reactions
- Transient ocular stinging or burning on instillation
- Conjunctival injection, watery/itchy eyes, dryness around eye, puffy eyes, eye irritation, styes
Pregnancy Undefined
Lactation Undefined
NO BOXED WARNINGS
Principal riskProphylaxis only; four-times-daily dosing
Cost, est. cash$10–$300/month
Generic entry1994
Classes and tags
Clinical profile
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Mechanism of action: Cromolyn ballicule
